A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)

NCT05704725 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Chorioretinal Vascular Disease

Interventions

DRUG: ABP 938
DRUG: Aflibercept

Sponsor

Amgen